Conrad Rasmus News Today : Breaking News, Live Updates & Top Stories | Vimarsana

NEW YORK & AACHEN, Germany, April 02, 2024--Protembis GmbH (Protembis), a privately-held emerging cardiovascular medical device company, announced today the enrollment of the first patient in the PROTEMBO Investigational Device Exemption (IDE) Pivotal Trial (NCT05873816). The trial will enroll between 250-500 randomized patients undergoing transcatheter aortic valve replacement (TAVR) in the USA and Europe with the ProtEmbo® System, an innovative next generation cerebral embolic protection devic

Protembis GmbH (Protembis), a privately-held emerging cardiovascular medical device company, announced today the completion of a ? 30 million Series B financing round to support the enrollment of the PROTEMBO Investigational Device Exemption (IDE)...

Cardiovascular medical device maker Protembis announced today that it completed a $32.6 million (€30 million) Series B financing round.

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

AACHEN, Germany, August 29, 2023--Protembis GmbH (Protembis) a privately-held emerging cardiovascular medical device company, announced today the appointment of Professor J Mocco MD, MS, FAANS, FAHA of Icahn School of Medicine at Mount Sinai, NY, USA as an independent member of their Board of Directors.